注射用母牛分枝杆菌(微卡)联合莫西沙星对耐多药肺结核患者的临床研究

Injection Mycobacterium vaccae(micro card)combined with moxifloxacin in clinical studies of patients with multi-drug resistant tuberculosis

目的探讨注射用母牛分枝杆菌(微卡)联合莫西沙星对耐多药肺结核患者的临床效果。方法该院2014年5月至2016年7月收治的108例耐多药肺结核患者,将患者随机分为对照组和观察组,各54例。对照组患者采用常规基础治疗,观察组使用注射用母牛分枝杆菌联合莫西沙星治疗,观察2组患者的病灶吸收改善、痰菌阴转率、用药后淋巴细胞亚群指标,以及不良反应等指标。结果治疗后,2组患者的病灶吸收程度,2、4、6、12个月的痰菌阴转率,淋巴细胞亚群指标CD3+、CD4+、CD8+、CD4+/CD8+等水平均有改善,且观察组患者改善情况明显优于对照组,差异均有统计学意义(P<0.05)。2组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论注射用母牛分枝杆菌联合莫西沙星对耐多药肺结核患者具有十分显著的疗效,明显改善患者的临床症状,促进病灶吸收,提高患者的生活质量,具有临床意义。

Objective To investigate the injection of Mycobacterium vaccae（micro card） combined with moxifloxacin clinical effect of MDR-TB patients.Methods A retrospective analysis of our hospital in May 2014 to July 2016 were treated Clinical data 108 cases of MDR-TB patients,in which the control group patients to take treatment on a regular basis,while 54 cases of the observation group were injected with Mycobacterium vaccae joint moxifloxacin therapy were observed in patients with foci improve sputum conversion rate after treatment lymphocyte subsets index and other indicators of adverse reactions.Results After treatment,the lesions extent of absorption of the two groups,2,4,6,12 month sputum conversion rate,lymphocyte subsets index CD3＋,CD4＋,CD8＋,CD4＋/CD8＋levels,and the situation had improved.Where in the improvement of the observation group were significantly better than the control group,data were statistically significant（P〈0.05）.And after treatment,the incidence of adverse reactions of the two groups were compared fairly basic,not statistically significant（P〉0.05）.Conclusion Mycobacterium injection cow joint moxifloxacin against MDR-TB patients has a very significant effect,can significantly improve the clinical symptoms,promote focus absorption and improve the quality of life of patients,help cure tuberculosis patients,is worthy of Applications.